Sangsangin Investment & Securities announced on March 11 that it is maintaining its “Buy” investment rating on Classys and has raised its target price to 87,000 won.

[Click e-Stock] "Now Is the Right Time to Buy... Classys Target Price Raised" View original image

Ha Taegi, a research analyst at Sangsangin Investment & Securities, stated, “Since last year, the share price has remained within a range of 45,000 to 77,000 won, but it is currently near the lower end of this range. With this year’s operating results expected to show high growth, there is upward momentum.” He added, “Although the Middle East war remains a variable, increasing uncertainty, Classys shares are seen as an increasingly stable buying opportunity as they approach the lower end of the trading range.”


This year, not only is there sales growth from existing products, but there are also positive effects from mergers and acquisitions (M&A). Ha explained, “Volumer entered the US market in the fourth quarter of 2024. Volumer entered Europe in June last year, and the microneedle RF device Quadsey entered Europe in August last year, both experiencing high growth. The Ilooda M&A last year resulted in a sales increase of 60 billion won, and with the acquisition of Medsystems earlier this month, consolidated sales are expected to rise by approximately 50 billion won.”


He continued, “Last year, the former Ilooda’s laser product, Lipot, was relaunched, leading to increased domestic sales. Quadsey, which was launched in July last year, is also contributing to this year’s sales growth, so domestic sales continue to rise. As a result, we expect operating profit to increase by 24.6% this year to 212.6 billion won.”


In particular, the expansion of Classys’s export regions is also a positive factor. Ha noted, “Last year, Ultraformer MPT and Volumer received European certification, and as they were launched in various European countries in the second half of last year, exports of equipment to Europe have begun in earnest. Considering Volumer, which was launched in the fourth quarter of 2024 following FDA approval, and Quadsey, which is being launched in the US market at the end of this month, exports to the North American market are also expected to gradually increase.”



He added, “In addition, in Japan, four products—Ultraformer MPT, Volumer, Lipot, and Quadsey—have all entered the market. In China, the company is preparing to enter the market with the goal of obtaining approval for Volumer from the National Medical Products Administration (NMPA) in the second half of this year, and for Ultraformer MPT in early next year, which means they are targeting diverse markets. Especially, with the acquisition of Brazilian aesthetic medical device distributor Medsystems completed earlier this month, we expect sales to rise by about 50 billion won over around 10 months this year.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing